|
Susan Desmond-Hellmann, MD, MPH, is the Chief Executive Officer of the Bill & Melinda Gates Foundation (BMGF). On December 17, 2013 The Bill & Melinda Gates Foundation announced that it had selected Susan Desmond-Hellmann, M.D., M.P.H., as its next chief executive officer. Desmond-Hellmann assumed her role on May 1, 2014. She was previously UCSF chancellor, appointed by UC President Mark Yudof on May 7, 2009, and held the post from August 3, 2009 to March 2014.〔 〕 She became the first woman chancellor of the nearly 150-year-old university. While chancellor, Desmond-Hellmann, an oncologist and biotechnology leader, held the Arthur and Toni Rembe Rock Distinguished Professorship at UCSF and oversaw all aspects of the university and medical center’s strategy and operations. Before that she was president of product development at Genentech (March 2004 through April 30, 2009), where she was credited for her role in the development of two of the first gene-targeted therapies for cancer, Avastin and Herceptin. Desmond-Hellmann also served as a member of Genentech’s executive committee, beginning in 1996. Desmond-Hellmann is a recognized leader on issues of higher education, public health, drug development, regulatory innovation and health policy. ==Career highlights== Desmond-Hellmann joined Genentech in 1995 as a clinical scientist, and she was named chief medical officer in 1996. In 1999, Desmond-Hellmann was named executive vice president of development and product operations. Prior to joining Genentech, Desmond-Hellmann was associate director of clinical cancer research at Bristol-Myers Squibb Pharmaceutical Research Institute. While at Bristol-Myers Squibb, she was the project team leader for Taxol. Desmond-Hellmann also has served as associate adjunct professor of epidemiology and biostatistics at UCSF. During her tenure at UCSF, Desmond-Hellmann spent two years as visiting faculty at the Uganda Cancer Institute, studying AIDS and cancer. She also spent two years in private practice before returning to clinical research. In April 2012, Desmond-Hellmann was honored with the Commonwealth Club of California’s 2012 Distinguished Citizen Award for her leadership at UCSF and Genentech. In October 2010, she was elected a member of the Institute of Medicine and inducted into the American Academy of Arts and Sciences. In January 2009, Desmond-Hellmann joined the Federal Reserve Bank of San Francisco’s Economic Advisory Council for a three-year term. She was named UCSF’s first woman chancellor and took the helm of the graduate health sciences university in August, 2009. In July 2008, Desmond-Hellmann was appointed to the California Academy of Sciences Board of Trustees. She was named to the Biotech Hall of Fame in 2007 and Healthcare Businesswomen’s Association Woman of the Year for 2006. Desmond-Hellmann was listed among Fortune magazine’s Top 50 Most Powerful Women in Business in 2001 and from 2003 to 2008. From 2004 to 2006, the Wall Street Journal listed Desmond-Hellmann as one of its Women to Watch. From 2005 to 2008, Desmond-Hellmann served a three-year term as a member of the American Association for Cancer Research board of directors, and from 2001 to 2009, she served on the executive committee of the board of directors of the Biotechnology Industry Organization. Desmond-Hellmann has served on the corporate board of Affymetrix since 2004.〔(【引用サイトリンク】accessdate=2009-08-03 )〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Susan Desmond-Hellmann」の詳細全文を読む スポンサード リンク
|